4,5-dibromo-2-(2-hydroxy-ethyl)-2H-pyridazin-3-one | 17802-48-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4,5-dibromo-2-(2-hydroxy-ethyl)-2H-pyridazin-3-one
• 英文别名: 4,5-dibromo-2-(2-hydroxyethyl)pyridazin-3-one；4,5-dibromo-2-(2-hydroxy-ethyl)-2H-pyridazin-3-one；3(2H)-Pyridazinone, 4,5-dibromo-2-(2-hydroxyethyl)-
• CAS: 17802-48-1
• 化学式: C₆H₆Br₂N₂O₂
• 分子量: 297.934
• InChiKey: VBHWPDNPCYKSSU-UHFFFAOYSA-N

物化性质

• 沸点：
  326.8±52.0 °C(Predicted)
• 密度：
  2.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4,5-dibromo-2-(2-hydroxy-ethyl)-2H-pyridazin-3-one 在 bis-triphenylphosphine-palladium(II) chloride 、 碳酸氢钠 、 sodium carbonate 作用下， 以 甲醇 、 水 、 乙腈 为溶剂， 反应 18.17h， 生成 a4 Integrin receptor antagonist 1
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel Pyridazinone-Based α₄ Integrin Receptor Antagonists

  摘要：

  A novel series of pyridazinone-functionalized phenylalanine analogues was prepared and evaluated for inhibition of cellular adhesion mediated by alpha(4)beta(1)/VCAM-1 and alpha(4)beta(7)/MAdCAM-1 interactions. Concise syntheses were developed and applied for exploration of structure-activity relationships pertaining to the pyridazinone ring as well as the N-acyl phenylalanine scaffold. Potent dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) were generated from an amide subseries; antagonists selective for alpha(4)beta(7) were identified from urea and carbamate-based subseries. The pharmacokinetic properties of selected members of the series have been determined in rats and demonstrate that the use of ester prodrugs and alterations to the amide linkage can lead to improved oral bioavailability in this series. An alpha(4),beta(7)-selective member of the carbamate subseries (36c), upon oral admininstration, demonstrated in vivo efficacy in the mouse DSS colitis model.

  DOI：

  10.1021/jm060031q
• 作为产物：
  描述：

  mucobromic acid 、 2-肼基乙醇 以 乙醇 为溶剂， 反应 2.0h， 以51%的产率得到4,5-dibromo-2-(2-hydroxy-ethyl)-2H-pyridazin-3-one
  参考文献：
  名称：

  Synthesis and Biological Evaluation of Novel Pyridazinone-Based α₄ Integrin Receptor Antagonists

  摘要：

  A novel series of pyridazinone-functionalized phenylalanine analogues was prepared and evaluated for inhibition of cellular adhesion mediated by alpha(4)beta(1)/VCAM-1 and alpha(4)beta(7)/MAdCAM-1 interactions. Concise syntheses were developed and applied for exploration of structure-activity relationships pertaining to the pyridazinone ring as well as the N-acyl phenylalanine scaffold. Potent dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) were generated from an amide subseries; antagonists selective for alpha(4)beta(7) were identified from urea and carbamate-based subseries. The pharmacokinetic properties of selected members of the series have been determined in rats and demonstrate that the use of ester prodrugs and alterations to the amide linkage can lead to improved oral bioavailability in this series. An alpha(4),beta(7)-selective member of the carbamate subseries (36c), upon oral admininstration, demonstrated in vivo efficacy in the mouse DSS colitis model.

  DOI：

  10.1021/jm060031q

文献信息

• スルホンアミド誘導体及びその医薬用途
  申请人：味の素株式会社

  公开号：JP2016037467A

  公开（公告）日：2016-03-22

  【課題】優れたα４インテグリン阻害作用を有する新規化合物を提供する。【解決手段】下記一般式（I）で示されるスルホンアミド誘導体、その医薬的に許容しうる塩又はそのプロドラッグ。（式中、ａ，ｂ，ｃ，ｄ，Ｄ，Ｅ，Ｒ１１，Ｂ，ｅ，ｆ，ｇ，ｈ及びＷは、明細書中で定義されるとおりである。）【選択図】なし

  提供具有优良α4整合素抑制作用的新化合物。通过下述通式（I）所示的磺酰胺衍生物，其医药上可接受的盐或其前药。（式中，a，b，c，d，D，E，R11，B，e，f，g，h和W如本说明书中所定义。）【选择图】无
• Pyridazinones as antagonists of alpha4 integrins
  申请人：Barbay Kent

  公开号：US20050192279A1

  公开（公告）日：2005-09-01

  The present invention relates to certain novel compounds of Formula (I): methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders.

  本发明涉及某些化合物的新颖结构，其化学式为（I）：制备这些化合物的方法，组合物，中间体及其衍生物以及用于治疗整合素介导的疾病。
• [EN] PYRIDAZINONES AS ANTAGONISTS OF A4 INTEGRINS<br/>[FR] PYRIDAZINONES EN TANT QU'ANTAGONISTES D'INTÉGRINES DOLLAR G(A)4
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2005077915A1

  公开（公告）日：2005-08-25

  The present invention relates to certain novel compounds of Formula (I): Formula (I) methods for preparing these compounds, compositions, intermediates and derivatives thereof and for the treatment of integrin mediated disorders.

  本发明涉及某些新型化合物的公式（I）：公式（I）制备这些化合物的方法、组成物、中间体和衍生物以及治疗整合素介导的疾病的方法。
• Synthesis and Biological Evaluation of Novel Pyridazinone-Based α₄ Integrin Receptor Antagonists
  作者：Yong Gong、J. Kent Barbay、Alexey B. Dyatkin、Tamara A. Miskowski、Edward S. Kimball、Stephen M. Prouty、M. Carolyn Fisher、Rosemary J. Santulli、Craig R. Schneider、Nathaniel H. Wallace、Scott A. Ballentine、William E. Hageman、John A. Masucci、Bruce E. Maryanoff、Bruce P. Damiano、Patricia Andrade-Gordon、Dennis J. Hlasta、Pamela J. Hornby、Wei He

  DOI：10.1021/jm060031q

  日期：2006.6.1

  A novel series of pyridazinone-functionalized phenylalanine analogues was prepared and evaluated for inhibition of cellular adhesion mediated by alpha(4)beta(1)/VCAM-1 and alpha(4)beta(7)/MAdCAM-1 interactions. Concise syntheses were developed and applied for exploration of structure-activity relationships pertaining to the pyridazinone ring as well as the N-acyl phenylalanine scaffold. Potent dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) were generated from an amide subseries; antagonists selective for alpha(4)beta(7) were identified from urea and carbamate-based subseries. The pharmacokinetic properties of selected members of the series have been determined in rats and demonstrate that the use of ester prodrugs and alterations to the amide linkage can lead to improved oral bioavailability in this series. An alpha(4),beta(7)-selective member of the carbamate subseries (36c), upon oral admininstration, demonstrated in vivo efficacy in the mouse DSS colitis model.